Please assess the completion status of the following clinical trial:

Trial Title: Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed invasive carcinoma of the breast~* Tumors must be less than or equal to 3cm in greatest dimension~* Must have node-negative breast cancer according to teh AJCC 7th edition~* ER/PR determination is required. ER- and PR-assays should be performed by immunohistochemical methods~* HER-2 positive: IHC 3+ or FISH \>2~* Bilateral breast cancers that individually meet eligibility criteria are allowed~* Patients should have tumor tissue available, and a tissue block of sufficient size to make 15 slides must be sent to DFCI for testing~* Less than or equal to 84 days from mastectomy or from axillary dissection or sentinel node biopsy if the patient's most extensive breast surgery was a breast-sparing procedure~* All tumor should be removed by either a modified radical mastectomy or a segmental mastectomy (lumpectomy), with either a sentinel node biopsy or axillary dissection~* 18 years of age or older~* ECOG Performance Status of 0 or 1~* Adequate bone marrow function, hepatic function, and renal function as outlined in protocol~* Left ventricular ejection fraction of greater than or equal to 50%~* Willingness to discontinue any hormonal agent prior to registration and while on study~* Willingness to discontinue sex hormonal therapy, e.g. birth control pills, prior to registration and while on study~* Patients with a history of ipsilateral DCIS are eligible if they were treated with wide-excision alone, without radiation therapy~* Patients undergoing breast conservation therapy must not have any contraindications to radiation therapy~Exclusion Criteria:~* Pregnant or nursing women~* Locally advanced tumors at diagnosis, including tumors fixed to the chest wall, peau d'orange, skin ulcerations/nodules, or clinical inflammatory changes~* History of prior chemotherapy in past 5 years~* History of prior trastuzumab therapy~* Active, unresolved infection~* Prior history of any other malignancy in the past 5 years, except for early stage tumors of the skin or cervix treated with curative intent~* Sensitivity to benzyl alcohol~* Grade 2 or greater neuropathy per NCI's CTCAv3.0. (Exception: Any chronic neurologic disorder will be looked at on a case-by-case basis by the study chair).~* Active cardiac disease as outlined in protocol.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer (Type: EXPERIMENTAL): 80 mg of paclitaxel per square meter of body-surface area weekly for 12 weeks and a loading dose of 4 mg of intravenous trastuzumab per kilogram of body weight on day 1, followed by 2 mg per kilogram weekly, for a total of 12 doses. After the completion of 12 weeks of treatment with Trastuzumab, the dosing of Trastuzumab could be continued on a weekly basis, or the regimen could be changed to 6 mg per kilogram every 3 weeks for 40 weeks to complete a full year of intravenous treatment with trastuzumab.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete